Suzetrigine for Pain Management: An Observational Study of Early Adoption Patterns.

Jamal Hasoon, Ivan Urits, Omar Viswanath, Farnad Imani, Alaa Abd-Elsayed
{"title":"Suzetrigine for Pain Management: An Observational Study of Early Adoption Patterns.","authors":"Jamal Hasoon, Ivan Urits, Omar Viswanath, Farnad Imani, Alaa Abd-Elsayed","doi":"10.64719/pb.16578","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Suzetrigine is a novel non-opioid analgesic initially approved for acute pain management. There has been growing interest in its potential applications for chronic pain conditions. As clinical awareness and accessibility expand, evaluating early outpatient prescribing patterns is essential to better understand its adoption and possible role in broader pain management strategies.</p><p><strong>Objective: </strong>To evaluate outpatient prescribing trends of suzetrigine at a single academic institution over 5 months to evaluate early adoption and prescription trends.</p><p><strong>Methods: </strong>This retrospective observational study examined outpatient prescriptions of suzetrigine from March 1, 2025, to July 31, 2025. Prescription counts were extracted from the institutional electronic medical record system and analyzed by month.</p><p><strong>Results: </strong>A total of 367 Suzetrigine prescriptions were written over the 5-month period. Monthly distribution was as follows:March: 3 prescriptionsApril: 44 prescriptionsMay: 97 prescriptionsJune: 93 prescriptionsJuly: 130 prescriptionsThere was a clear upward trend in prescribing from March to July. This increase may reflect growing provider familiarity and favorable patient response to the medication.</p><p><strong>Conclusion: </strong>Suzetrigine outpatient prescribing has increased significantly over a short time frame at our institution. Continued monitoring of prescription trends, indications, and patient outcomes will be essential as this medication becomes more widely utilized in pain management.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"56 2","pages":"52-57"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976945/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.64719/pb.16578","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Suzetrigine is a novel non-opioid analgesic initially approved for acute pain management. There has been growing interest in its potential applications for chronic pain conditions. As clinical awareness and accessibility expand, evaluating early outpatient prescribing patterns is essential to better understand its adoption and possible role in broader pain management strategies.

Objective: To evaluate outpatient prescribing trends of suzetrigine at a single academic institution over 5 months to evaluate early adoption and prescription trends.

Methods: This retrospective observational study examined outpatient prescriptions of suzetrigine from March 1, 2025, to July 31, 2025. Prescription counts were extracted from the institutional electronic medical record system and analyzed by month.

Results: A total of 367 Suzetrigine prescriptions were written over the 5-month period. Monthly distribution was as follows:March: 3 prescriptionsApril: 44 prescriptionsMay: 97 prescriptionsJune: 93 prescriptionsJuly: 130 prescriptionsThere was a clear upward trend in prescribing from March to July. This increase may reflect growing provider familiarity and favorable patient response to the medication.

Conclusion: Suzetrigine outpatient prescribing has increased significantly over a short time frame at our institution. Continued monitoring of prescription trends, indications, and patient outcomes will be essential as this medication becomes more widely utilized in pain management.

舒三嗪用于疼痛管理:早期采用模式的观察性研究。
背景:舒三嗪是一种新型非阿片类镇痛药,最初被批准用于急性疼痛治疗。人们对它在慢性疼痛方面的潜在应用越来越感兴趣。随着临床意识和可及性的扩大,评估早期门诊处方模式对于更好地了解其采用和在更广泛的疼痛管理策略中可能发挥的作用至关重要。目的:评价某学术机构门诊近5个月的舒三嗪处方趋势,以评价舒三嗪的早期应用和处方趋势。方法:本回顾性观察研究调查了2025年3月1日至2025年7月31日门诊使用舒三嗪的处方。从机构电子病历系统中提取处方计数,按月进行分析。结果:5个月期间共开处方367张。月分布情况如下:3月3方、4月44方、5月97方、6月93方、7月130方。3 - 7月处方数量呈明显上升趋势。这一增长可能反映了越来越多的提供者熟悉和良好的患者对药物的反应。结论:苏泽三嗪门诊处方在短时间内显著增加。随着这种药物在疼痛管理中的应用越来越广泛,对处方趋势、适应症和患者结果的持续监测将是必不可少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书